首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MPIF2 |
| Uniprot No | O00175 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-104aa |
| 氨基酸序列 | VVIPSPCCMFFVSKRIPENRVVSYQLSSRSTCLKGGVIFTTKKGQQFCGD PKQEWVQRYMKNLDAKQKKASPRARAVA |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MPIF2(Macrophage Inflammatory Protein-2)重组蛋白的参考文献示例(注：文献信息为模拟概括，实际引用时请核实准确性)：
1. **文献名称**: "Cloning and Expression of Recombinant Human MPIF-2 in E. coli for Functional Characterization"
**作者**: Smith A.B., et al.
**摘要**: 本研究报道了人源MPIF2基因在大肠杆菌中的克隆与重组表达，优化了纯化流程，并通过体外趋化实验证实重组蛋白对中性粒细胞具有趋化活性。
2. **文献名称**: "Structural Analysis of MPIF-2 Reveals Key Residues for Receptor Binding"
**作者**: Lee C., et al.
**摘要**: 通过X射线晶体学解析了重组MPIF2的三维结构，鉴定了其与CXCR2受体结合的关键氨基酸残基，为靶向药物设计提供了结构基础。
3. **文献名称**: "MPIF-2 in Acute Lung Injury: Recombinant Protein Attenuates Neutrophil Infiltration in Murine Models"
**作者**: Johnson R.T., et al.
**摘要**: 在小鼠急性肺损伤模型中，外源性重组MPIF2通过调控中性粒细胞迁移显著减轻炎症反应，提示其潜在治疗价值。
4. **文献名称**: "High-Yield Production of Biologically Active MPIF-2 Using Mammalian Expression Systems"
**作者**: Gupta S., et al.
**摘要**: 开发了一种基于哺乳动物细胞的重组MPIF2高效表达系统，所得蛋白糖基化修饰完整，体外活性较原核表达产物显著提高。
**建议**：实际文献检索可使用PubMed或Google Scholar，以“MPIF2 recombinant”“CXCL2 expression”或“MIP-2 chemokine”为关键词，并注意MPIF2可能与CXCL2/GROβ为同源蛋白。部分研究可能使用别名(如MIP-2α)，需扩展检索策略。
MPIF2 (Myeloid Progenitor Inhibitory Factor 2), also known as CCL21. is a chemokine belonging to the CC subfamily. It plays a pivotal role in immune regulation and leukocyte trafficking by interacting with its receptor, CCR7. Structurally, it consists of a conserved N-terminal region and a C-terminal heparin-binding domain, facilitating interactions with glycosaminoglycans for tissue localization. CCL21 is primarily expressed in secondary lymphoid organs, including lymph nodes and the spleen, where it guides dendritic cells and naïve T cells to specific zones for antigen presentation and immune activation.
Recombinant MPIF2/CCL21 is produced using expression systems like *E. coli* or mammalian cells, ensuring proper folding and post-translational modifications for functional activity. Its production enables researchers to study chemotaxis, immune cell homing, and lymphoid tissue organization. In disease contexts, CCL21 has dual roles: it supports anti-tumor immunity by recruiting immune cells but may also promote tumor metastasis through angiogenesis or creating immunosuppressive microenvironments. Additionally, it is implicated in chronic inflammatory conditions, such as rheumatoid arthritis and atherosclerosis.
Therapeutic exploration includes leveraging CCL21 in cancer vaccines or inhibiting its signaling to block pathological inflammation. Its recombinant form remains a critical tool for dissecting chemokine biology and developing targeted immunotherapies.
×
